Please fill out the form below and we will gladly respond as soon as possible.
Synovial sarcoma is a rare and aggressive soft tissue cancer that most often develops near the joints of the arms or legs. In very rare cases, however, it can appear in unusual locations — including the skull and brain region. A newly published case report describes a patient diagnosed with primary cranial synovial sarcoma who […]
Synovial sarcoma is a rare and aggressive soft tissue cancer, but new research is helping us better understand how it behaves—and how it may be treated in the future. A recent study using advanced single-cell RNA sequencing has identified four distinct subtypes of synovial sarcoma, each with unique biological features and potential treatment pathways. Why […]
What the UK’s Rare Cancers Bill Means for the Synovial Sarcoma Community For decades, patients diagnosed with rare cancers have faced a structural disadvantage. Fewer treatment options. Fewer clinical trials. Less research funding. Now a new law in the United Kingdom aims to change that. The Rare Cancers Bill, introduced by Dr Scott Arthur MP, […]
Synovial sarcoma is a rare and often aggressive cancer that can become difficult to treat once it spreads. Traditional chemotherapy options are limited, and outcomes for metastatic disease remain poor. New research is exploring whether advanced T-cell therapies may offer another option. A recent clinical trial evaluated afamitresgene autoleucel (afami-cel), an engineered T-cell therapy designed […]
Zelluna, a Norway-based biotechnology company, has announced the submission of a Clinical Trial Application (CTA) in the United Kingdom for ZI-MA4-1 (ZIMA-101), a first-in-human cell therapy study that will include patients with synovial sarcoma. While this trial is still in its earliest phase, it represents a notable scientific development for the synovial sarcoma community. What […]
A landmark study just published in Nature Communications finally pinpointed the exact “cell of origin” for synovial sarcoma — a rare, primitive fibroblast that still carries embryonic markers (Hic1⁺ Pdgfra⁺ Lgr5⁺). Breaking 2025 Research: Read the entire article here. Learn more about our world-renowned registry efforts here.
The Synovial Sarcoma Foundation is pleased to highlight a significant milestone at the Children’s Hospital of Philadelphia (CHOP), where pediatric oncologist and Synovial Sarcoma Foundation Board Member, Dr. Theodore W. Laetsch, has been awarded a prestigious $1 million multi-year grant from the National Cancer Institute (NCI). This funding aims to accelerate research and treatment development […]
The Synovial Sarcoma Foundation is dedicated to supporting cutting-edge research that advances treatment options for this rare and aggressive cancer. Recent findings published in The EMBO Journal highlight a promising new strategy: using drug blockers to target a problematic protein involved in synovial sarcoma’s genetics. Synovial sarcoma primarily develops in soft tissues such as muscles […]